Neoadjuvant docetaxel and capecitabine in patients with high risk/locally advanced prostate cancer: Preliminary results of a phase II study.

被引：0
|
作者：
Friedman, JD
Vaishampayan, U
Montie, J
Shah, R
Sarkar, F
Smith, D
Hussain, M
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Wayne State Univ, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：438S / 438S
页数：1
相关论文
共 50 条
  • [21] Phase II study of neoadjuvant docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer (LABC)
    Perez-Manga, G.
    Mendez, M.
    Palomero, M. I.
    Quiben, R.
    Belon, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Intensified neoadjuvant chemoradiotherapy (CRT) with capecitabine and irinotecan in patients with locally advanced rectal cancer (LARC): A phase I/II study.
    Klautke, G
    Foitzik, T
    Ludwig, K
    Klar, EJM
    Fietkau, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 292S - 292S
  • [23] Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer
    Hussain, M
    Smith, DC
    El-Rayes, BF
    Du, W
    Vaishampayan, U
    Fontana, J
    Sakr, W
    Wood, D
    UROLOGY, 2003, 61 (04) : 774 - 780
  • [24] Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: Results of a phase I/II study
    Konety, BR
    Eastham, JA
    Reuter, VE
    Scardino, PT
    Donat, SM
    Dalbagni, G
    Russo, P
    Herr, HW
    Schwartz, L
    Kantoff, PW
    Scher, H
    Kelly, WK
    JOURNAL OF UROLOGY, 2004, 171 (02): : 709 - 713
  • [25] Effect of neoadjuvant docetaxel treatment for locally advanced prostate cancer on miRNA expression: A pilot study.
    Falzarano, Sara Moscovita
    Zhou, Ming
    Carver, Paula
    Klein, Eric A.
    Dreicer, Robert
    Magi-Galluzzi, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [26] Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer
    Dreicer, R
    Magi-Galluzzi, C
    Zhou, M
    Rothaermel, J
    Reuther, A
    Ulchaker, J
    Zippe, C
    Fergany, A
    Klein, EA
    UROLOGY, 2004, 63 (06) : 1138 - 1142
  • [27] A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
    Matsuda, Chu
    Kudo, Toshihiro
    Morimoto, Yoshihiro
    Kagawa, Yoshinori
    Tei, Mitsuyoshi
    Ide, Yoshihito
    Miyoshi, Norikatsu
    Takahashi, Hidekazu
    Uemura, Mamoru
    Takemasa, Ichiro
    Satoh, Taroh
    Mizushima, Tsunekazu
    Murata, Kohei
    Doki, Yuichiro
    Eguchi, Hidetoshi
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2023, 7 (01): : 81 - 90
  • [28] Capecitabine plus docetaxel plus bevacizumab as neoadjuvant therapy for invasive breast cancer: results of a phase II pilot study.
    Greil, R.
    Moik, M.
    Reitsamer, R.
    Ressler, S.
    Stoll, M.
    Namberger, K.
    Menzel, C.
    Mlineritsch, B.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S188 - S188
  • [29] Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage).
    Bellet, M
    Munoz, M
    Pelegri, A
    Corominas, J
    Bellosillo, B
    Tusquets, I
    Fabregat, X
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 64S - 64S
  • [30] Neoadjuvant Radiochemotherapy with Capecitabine and Oxaliplatin plus bevacizumab in locally advanced Rectal Cancer - Results of a phase II study
    Dellas, K.
    Hoehler, T.
    Riesenbeck, D.
    Reese, T.
    Wuerschtnidt, F.
    Engel, E.
    Roedel, C.
    Wagner, W.
    Richter, M.
    Dunst, J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 : 51 - 51
12345